Weekly Analysts’ Ratings Updates for Quanterix (QTRX)

Several analysts have recently updated their ratings and price targets for Quanterix (NASDAQ: QTRX):

• 8/17/2026 – Quanterix had its price target lowered by Canaccord Genuity Group Inc. from $4.00 to $3.00. They now have a “hold” rating on the stock.
• 8/15/2026 – Quanterix was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/11/2026 – Quanterix had its price target lowered by TD Cowen from $4.00 to $3.00. They now have a “hold” rating on the stock.
• 8/7/2026 – Quanterix had its “sell (e+)” rating reaffirmed by Weiss Ratings.

Quanterix Corporation is a life sciences and diagnostics company specializing in ultra-sensitive digital immunoassay platforms. Its proprietary Single Molecule Array (Simoa) technology enables researchers to detect and quantify proteins, peptides and nucleic acids at femtomolar concentrations, offering sensitivity that surpasses traditional immunoassay methods. By translating single-molecule detection into routine laboratory workflows, Quanterix aims to accelerate biomarker discovery and the development of novel diagnostics and therapeutics.

The company’s core product portfolio includes the Simoa HD-1 and HD-X Analyzers, which automate high-throughput digital immunoassays for quantifying low-abundance biomarkers.